For research use only
| Cat No. | ABC-TC3889 |
| Product Type | Diseased Human Peripheral Blood Mononuclear Cells |
| Cell Type | Mononuclear Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Mantle Cell Lymphoma |
| Storage | Liquid Nitrogen |
Human Mantle Cell Lymphoma PBMCs (Newly Diagnosed/Untreated) support lymphoma immunology, biomarkers, and therapy evaluation in patient samples. in lab.
Human Mantle Cell Lymphoma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated) are derived from the peripheral blood of patients with newly diagnosed mantle cell lymphoma (MCL) who have not received any treatment. These cells are often characterized by t(11;14)(q13;q32) translocation leading to cyclin D1 overexpression. They contain malignant transformed cells of B-cell non-Hodgkin’s lymphoma, and show high expression of CD20, CD5, cyclin D1 (CCND1), SOX11. Morphologically, these cells usually appear as lymphocytes with medium sized, irregular nuclei and condensed chromatin, and some of them can be seen as “blastoid” variants, showing invasive growth characteristics. Their functional abnormalities are manifested as enhanced anti-apoptosis ability, dysregulated proliferation and immune escape. In translational and clinical studies, these samples are widely used to analyze gene expression profiles, investigate disease progression and immune responses, and evaluate emerging therapeutic strategies in mantle cell lymphoma.
| Species | Human |
| Cat.No | ABC-TC3889 |
| Product Category | Primary Cells |
| Size/Quantity | 1 vial |
| Cell Type | Mononuclear Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Mantle Cell Lymphoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Diseased Human Peripheral Blood Mononuclear Cells |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Human Mantle Cell Lymphoma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated) can be used as an in vitro cell model to study the pathogenesis of mantle cell lymphoma (MCL), such as dysregulated proliferation, apoptosis resistance and signaling pathway abnormalities (including BCR, NF-κB and PI3K pathways) of MCL. These cells can also be used to evaluate the efficacy and resistance mechanism of targeted drugs such as BTK inhibitors (such as ibrutinib) and BCL-2 inhibitors (such as venetoclax).
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).